Table 4.
HPV species/type | Controls n=10 |
PeIN n=5 |
|||||
---|---|---|---|---|---|---|---|
|
|
||||||
Normal genital skin | Normal genital skin | PeIN | |||||
|
|
|
|||||
12mo prior | 6mo prior | Index visit | 12mo prior | 6mo prior | Index visit | Index visit | |
|
|
|
|||||
No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | |
Any β-HPV type | 8 (80.0) | 8 (80.0) | 5 (50.0) | 4 (80.0) | 5 (100) | 5 (100) | 2 (40.0) |
β1 | |||||||
Any β1 | 7 (77.8) | 6 (60.0) | 4 (40.0) | 4 (80.0) | 4 (80.0) | 3 (60.0) | 2 (40.0) |
HPV5 | 4 (44.4) | 3 (30.0) | 2 (20.0) | 2 (40.0) | 3 (60.0) | 3 (60.0) | 0 (0) |
HPV8 | 4 (44.4) | 3 (30.0) | 2 (20.0) | 1 (20.0) | 2 (40.0) | 1 (20.0) | 0 (0) |
HPV12 | 2 (22.2) | 1 (10.0) | 1 (10.0) | 2 (40.0) | 1 (20.0) | 1 (20.0) | 0 (0) |
HPV14 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (20.0) | 0 (0) |
HPV19 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
HPV20 | 0 (0) | 1 (10.0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
HPV21 | 0 (0) | 0 (0) | 0 (0) | 1 (20.0) | 1 (20.0) | 1 (20.0) | 2 (40.0) |
HPV24 | 2 (22.2) | 1 (10.0) | 1 (10.0) | 1 (20.0) | 0 (0) | 0 (0) | 0 (0) |
HPV25 | 0 (0) | 0 (0) | 1 (10.0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
HPV36 | 0 (0) | 1 (10.0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
HPV47 | 5 (55.6) | 6 (60.0) | 3 (30.0) | 1 (20.0) | 0 (0) | 1 (20.0) | 0 (0) |
HPV93 | 1 (11.1) | 1 (10.0) | 2 (20.0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
β2 | |||||||
Any β2 | 8 (88.9) | 5 (50.0) | 3 (30.0) | 4 (80.0) | 5 (100) | 3 (60.0) | 2 (40.0) |
HPV9 | 2 (22.2) | 2 (20.0) | 2 (20.0) | 1 (20.0) | 1 (20.0) | 0 (0) | 1 (20.0) |
HPV15 | 1 (11.1) | 0 (0) | 0 (0) | 0 (0) | 1 (20.0) | 0 (0) | 0 (0) |
HPV17 | 1 (11.1) | 1 (10.0) | 0 (0) | 2 (40.0) | 3 (60.0) | 1 (20.0) | 1 (20.0) |
HPV22 | 3 (33.3) | 1 (10.0) | 2 (20.0) | 1 (20.0) | 1 (20.0) | 0 (0) | 0 (0) |
HPV23 | 2 (22.2) | 2 (20.0) | 2 (20.0) | 2 (40.0) | 2 (40.0) | 2 (40.0) | 0 (0) |
HPV37 | 1 (11.1) | 1 (10.0) | 1 (10.0) | 1 (20.0) | 0 (0) | 0 (0) | 0 (0) |
HPV38 | 3 (33.3) | 1 (10.0) | 2 (20.0) | 1 (20.0) | 2 (40.0) | 2 (40.0) | 1 (20.0) |
HPV80 | 0 (0) | 0 (0) | 0 (0) | 1 (20.0) | 0 (0) | 0 (0) | 1 (20.0) |
β3 | |||||||
Any β3 | 2 (22.2) | 1 (10.0) | 0 (0) | 1 (20.0) | 0 (0) | 0 (0) | 0 (0) |
HPV49 | 1 (11.1) | 1 (10.0) | 0 (0) | 1 (20.0) | 0 (0) | 0 (0) | 0 (0) |
HPV75 | 2 (22.2) | 0 (0) | 0 (0) | 1 (20.0) | 0 (0) | 0 (0) | 0 (0) |
HPV76 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
β4 | |||||||
HPV92 | 0 (0) | 0 (0) | 0 (0) | 1 (20.0) | 1 (20.0) | 1 (20.0) | 0 (0) |
β5 | |||||||
HPV96 | 0 (0) | 0 (0) | 0 (0) | 1 (20.0) | 0 (0) | 0 (0) | 0 (0) |
Multiple β-HPV types | |||||||
≥2 types | 7 (70.0) | 5 (50.0) | 3 (30.0) | 4 (80.0) | 4 (80.0) | 2 (40.0) | 1 (20.0) |
α-HPV typea | |||||||
HPV16/18 | 1 (10.0) | 1 (10.0) | 1 (10.0) | 1 (20.0) | 1 (20.0) | 2 (40.0) | 2 (40.0) |
Note: Sample sizes change depending on specimen availability and validity of HPV results.
Surface of normal genital skin and EGL specimens were evaluated for α-HPV using Linear Array